Evidence map›Paper›PMID 27179635›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2016

Periadventitial drug delivery for the prevention of intimal hyperplasia following open surgery.

Mirnal A Chaudhary, Lian-Wang Guo, Xudong Shi, Guojun Chen, Shaoqin Gong, Bo Liu, K Craig Kent

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Promising Adventitia in Atherosclerosis.Current vascular pharmacology · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Heparin-functionalized polymer graft surface eluting MK2 inhibitory peptide to improve hemocompatibility and anti-neointimal activity.Journal of controlled release : official journal of the Controlled Release Society · 2017
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mirnal A ChaudharyDepartment of Surgery, Wisconsin Institute for Medical Research, University of Wisconsin, 1111 Highland Ave, Madison, WI 53705, USA.
Lian-Wang GuoDepartment of Surgery, Wisconsin Institute for Medical Research, University of Wisconsin, 1111 Highland Ave, Madison, WI 53705, USA. Electronic address: guo@surgery.wisc.edu.
Xudong ShiDepartment of Surgery, Wisconsin Institute for Medical Research, University of Wisconsin, 1111 Highland Ave, Madison, WI 53705, USA.
Guojun ChenDepartment of Materials Science and Engineering, Department of Biomedical Engineering, Wisconsin Institute of Discovery, University of Wisconsin, 330 North Orchard St, Madison, WI 53715, USA.
Shaoqin GongDepartment of Materials Science and Engineering, Department of Biomedical Engineering, Wisconsin Institute of Discovery, University of Wisconsin, 330 North Orchard St, Madison, WI 53715, USA.
Bo LiuDepartment of Surgery, Wisconsin Institute for Medical Research, University of Wisconsin, 1111 Highland Ave, Madison, WI 53705, USA.
K Craig KentDepartment of Surgery, Wisconsin Institute for Medical Research, University of Wisconsin, 1111 Highland Ave, Madison, WI 53705, USA; Department of Surgery, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, WI 53792, USA. Electronic address: kent@surgery.wisc.edu.
Wisconsin Institutes for Discovery · USUW Health University Hospital · US

Funding

Institutional Clinical and Translational Science AwardUL1TR000427 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2012 to 2016
$32.2M
TGF-Beta in Intimal Hyperplasia after Vascular BypassR01HL068673 · NHLBI · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI KENT, K CRAIG · 2002 to 2017
$4.9M
Vascular Surgery Research Training ProgramT32HL110853 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI MATSUMURA, JON STEVEN · 2012 to 2021
$2.6M
Development of unimolecular nanoparticle-mediated periadventitial drug delivery system for sustained and targeted inhibition of intimal hyperplasia following open vascular reconstructionR01HL129785 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI GONG, SHAOQIN -, GUO, LIANWANG · 2016 to 2019
$2.0M
Sigma-1 Chaperone-Mediated in vivo Neuroprotection in the RetinaR01EY022678 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI GUO, LIANWANG · 2012 to 2016
$1.7M
Vascular smooth muscle cell apoptosis in intimal hyperplasiaR01HL122562 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI LIU, BO · 2015 to 2018
$1.6M
BET Bromodomain proteins as Novel Epigenetic Targets for prevention of Intimal Hyperplasia after Vascular SurgeryR01HL133665 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI GUO, LIANWANG · 2016 to 2019
$1.6M
NCATS NIH HHS UL1 TR000427NEI NIH HHS R01 EY022678NHLBI NIH HHS R01 HL068673NHLBI NIH HHS R01 HL122562NHLBI NIH HHS R01 HL129785NHLBI NIH HHS R01 HL133665NHLBI NIH HHS T32 HL110853
6 · The paper itself

Abstract

backgroundIntimal hyperplasia (IH) remains a major cause of poor patient outcomes after surgical revascularization to treat atherosclerosis. A multitude of drugs have been shown to prevent the development of IH. Moreover, endovascular drug delivery following angioplasty and stenting has been achieved with a marked diminution in the incidence of restenosis. Despite advances in endovascular drug delivery, there is currently no clinically available method of periadventitial drug delivery suitable for open vascular reconstructions. Herein we provide an overview of the recent literature regarding innovative polymer platforms for periadventitial drug delivery in preclinical models of IH as well as insights about barriers to clinical translation.

methodsA comprehensive PubMed search confined to the past 15years was performed for studies of periadventitial drug delivery. Additional searches were performed for relevant clinical trials, patents, meeting abstracts, and awards of NIH funding.

resultsMost of the research involving direct periadventitial delivery without a drug carrier was published prior to 2000. Over the past 15years there have been a surge of reports utilizing periadventitial drug-releasing polymer platforms, most commonly bioresorbable hydrogels and wraps. These methods proved to be effective for the inhibition of IH in various animal models (e.g. balloon angioplasty, wire injury, and vein graft), but very few have advanced to clinical trials. There are a number of barriers that may account for this lack of translation. Promising new approaches including the use of nanoparticles will be described.

conclusionsNo periadventitial drug delivery system has reached clinical application. For periadventitial delivery, polymer hydrogels, wraps, and nanoparticles exhibit overlapping and complementary properties. The ideal periadventitial delivery platform would allow for sustained drug release yet exert minimal mechanical and inflammatory stresses to the vessel wall. A clinically applicable strategy for periadventitial drug delivery would benefit thousands of patients undergoing open vascular reconstruction each year.

Indexed as

Drug Delivery SystemsAdventitiaAnimalsHumansHydrogelsHyperplasiaNanoparticlesPostoperative ComplicationsSurgical Procedures, OperativeTunica IntimaHydrogelsHydrogelIntimal hyperplasiaNanoparticlesOpen surgeryPeriadventitial drug deliveryWrap

Identifiers

PMID27179635
PMCPMC4912910
OpenAlexW2351861838

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.